TTK program and SynergyFinder™ presented at TAT 2015 conference in Paris
NTRC is exhibiting sponsor of the 13th international conference on Targeted Anticancer Therapies (TAT), that we be held in Paris (France) from March 2nd to 4th.
NTRC Services will participate in the commercial exhibition and two posters will be presented. One poster is on SynergyFinder™; the second on NTRC’s drug discovery program on TTK kinase inhibitors, in collaboration with the groups of Rene Medema at the Netherlands Cancer Institute in Amsterdam and Geert Kops at the University Medical Center Utrecht.
The posters will be displayed during the whole conference, from Monday to Wednesday afternoon, while there is a poster viewing session scheduled in the program on Monday 2nd, from 6 to 7.30 p.m., where you can meet NTRC scientists at their posters.
Poster P6.14: Identification of selective inhibitors of the spindle assembly checkpoint kinase TTK (Mps1) for treatment of triple negative breast cancer
Poster P8.05: Selective targeting of CTNBB1-, KRAS- or MYC-driven cell growth by combinations of existing drugs
At our booth in the exhibition area you will find information on the drug discovery services of NTRC, i.e., Oncolines™, SynergyFinder™ and ResidenceTimer™, our screening assay for IDO1 and TDO, NFK Green™, as well as information on the services represented by NTRC of Carna, i.e., RPPA and QuickScout™.
Guido Zaman, Rogier Buijsman and Suzanne van Gerwen will attend the conference.
We look forward to meet you in Paris!